Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system

Haematologica. 2016 Oct;101(10):e427-e428. doi: 10.3324/haematol.2016.150714.

Authors

Thomas Prebet¹, Pierre Fenaux², Norbert Vey³; Groupe Francophone des Myelodysplasies

Affiliations

¹ Smilow Cancer center at Yale New Haven Hospital, CT, USA Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France thomas.prebet@yale.edu.
² Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France Service Hematologie Senior, Hopital Saint Louis, Paris, France.
³ Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France Service Hematologie 2, Institut Paoli-Calmettes, Marseille, France.

No abstract available

Keywords: acute myeloid leukemia; cytogenics and molecular genetics; hypomethylating agents; melodysplastic syndromes; stem cell transplantation.

Publication types

Letter

MeSH terms

Aged
Antimetabolites, Antineoplastic / therapeutic use*
Azacitidine / therapeutic use*
Cohort Studies
Female
Follow-Up Studies
Humans
Male
Middle Aged
Myelodysplastic Syndromes / diagnosis*
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / mortality
North America / epidemiology
Predictive Value of Tests
Reproducibility of Results
Severity of Illness Index*
Treatment Failure
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Azacitidine